218 related articles for article (PubMed ID: 36537080)
21.
Piedimonte S; Power J; Foulkes WD; Weber E; Palma L; Schiavi A; Ambrosio E; Konci R; Gilbert L; Jardon K; Baret L; Zeng X
Int J Gynecol Cancer; 2020 Nov; 30(11):1757-1761. PubMed ID: 32759180
[TBL] [Abstract][Full Text] [Related]
22. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
Maistro S; Teixeira N; Encinas G; Katayama ML; Niewiadonski VD; Cabral LG; Ribeiro RM; Gaburo Junior N; de Gouvêa AC; Carraro DM; Sabino EC; Diz MD; Chammas R; de Bock GH; Folgueira MA
BMC Cancer; 2016 Dec; 16(1):934. PubMed ID: 27914478
[TBL] [Abstract][Full Text] [Related]
23. BRCA1 and BRCA2 genes mutations among high risk breast cancer patients in Jordan.
Abu-Helalah M; Azab B; Mubaidin R; Ali D; Jafar H; Alshraideh H; Drou N; Awidi A
Sci Rep; 2020 Oct; 10(1):17573. PubMed ID: 33067490
[TBL] [Abstract][Full Text] [Related]
24. BRCA1 and BRCA2 mutations and clinical interpretation in 398 ovarian cancer patients: comparison with breast cancer variants in a similar population.
Cardoso FC; Goncalves S; Mele PG; Liria NC; Sganga L; Diaz Perez I; Podesta EJ; Solano AR
Hum Genomics; 2018 Aug; 12(1):39. PubMed ID: 30103829
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).
Harter P; Hauke J; Heitz F; Reuss A; Kommoss S; Marmé F; Heimbach A; Prieske K; Richters L; Burges A; Neidhardt G; de Gregorio N; El-Balat A; Hilpert F; Meier W; Kimmig R; Kast K; Sehouli J; Baumann K; Jackisch C; Park-Simon TW; Hanker L; Kröber S; Pfisterer J; Gevensleben H; Schnelzer A; Dietrich D; Neunhöffer T; Krockenberger M; Brucker SY; Nürnberg P; Thiele H; Altmüller J; Lamla J; Elser G; du Bois A; Hahnen E; Schmutzler R
PLoS One; 2017; 12(10):e0186043. PubMed ID: 29053726
[TBL] [Abstract][Full Text] [Related]
26. Genetic testing in Poland and Ukraine: should comprehensive germline testing of
Nguyen-Dumont T; Karpinski P; Sasiadek MM; Akopyan H; Steen JA; Theys D; Hammet F; Tsimiklis H; Park DJ; Pope BJ; Slezak R; Stembalska A; Pesz K; Kitsera N; Siekierzynska A; Southey MC; Myszka A
Genet Res (Camb); 2020 Aug; 102():e6. PubMed ID: 32772980
[TBL] [Abstract][Full Text] [Related]
27. Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations.
Singh J; Thota N; Singh S; Padhi S; Mohan P; Deshwal S; Sur S; Ghosh M; Agarwal A; Sarin R; Ahmed R; Almel S; Chakraborti B; Raina V; DadiReddy PK; Smruti BK; Rajappa S; Dodagoudar C; Aggarwal S; Singhal M; Joshi A; Kumar R; Kumar A; Mishra DK; Arora N; Karaba A; Sankaran S; Katragadda S; Ghosh A; Veeramachaneni V; Hariharan R; Mannan AU
Breast Cancer Res Treat; 2018 Jul; 170(1):189-196. PubMed ID: 29470806
[TBL] [Abstract][Full Text] [Related]
28. Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer.
Chao A; Chang TC; Lapke N; Jung SM; Chi P; Chen CH; Yang LY; Lin CT; Huang HJ; Chou HH; Liou JD; Chen SJ; Wang TH; Lai CH
Oncotarget; 2016 Dec; 7(51):85529-85541. PubMed ID: 27907908
[TBL] [Abstract][Full Text] [Related]
29. Using next-generation sequencing (NGS) platform to diagnose pathogenic germline BRCA1/2 mutations from archival tumor specimens.
Ong PY; Poon SL; Tan KT; Putti TC; Ow SGW; Chen SJ; Chen CH; Lee SC
Gynecol Oncol; 2019 Nov; 155(2):275-279. PubMed ID: 31481248
[TBL] [Abstract][Full Text] [Related]
30. Guideline-Based, Multi-Gene Panel Germline Genetic Testing for at-Risk Patients with Breast Cancer.
Abdel-Razeq H; Abujamous L; Al-Azzam K; Abu-Fares H; Bani Hani H; Alkyam M; Sharaf B; Elemian S; Tamimi F; Abuhijla F; Edaily S; Salama O; Abdulelah H; Daoud R; Abubaker M; Al-Atary A
Breast Cancer (Dove Med Press); 2023; 15():1-10. PubMed ID: 36660366
[TBL] [Abstract][Full Text] [Related]
31. Molecular characteristics of breast tumors in patients screened for germline predisposition from a population-based observational study.
Nacer DF; Vallon-Christersson J; Nordborg N; Ehrencrona H; Kvist A; Borg Å; Staaf J
Genome Med; 2023 Apr; 15(1):25. PubMed ID: 37060015
[TBL] [Abstract][Full Text] [Related]
32. Germline testing of
Woodward ER; Lalloo F; Forde C; Pugh S; Burghel GJ; Schlecht H; Harkness EF; Howell A; Howell SJ; Gandhi A; Evans DG
J Med Genet; 2024 Mar; 61(4):385-391. PubMed ID: 38123987
[TBL] [Abstract][Full Text] [Related]
33. Extended gene panel testing in lobular breast cancer.
van Veen EM; Evans DG; Harkness EF; Byers HJ; Ellingford JM; Woodward ER; Bowers NL; Wallace AJ; Howell SJ; Howell A; Lalloo F; Newman WG; Smith MJ
Fam Cancer; 2022 Apr; 21(2):129-136. PubMed ID: 33763779
[TBL] [Abstract][Full Text] [Related]
34. Patterns and Prevalence of Germline
Abdel-Razeq H; Abujamous L; Jadaan D
J Oncol; 2020; 2020():8362179. PubMed ID: 32733560
[TBL] [Abstract][Full Text] [Related]
35. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey.
Demir S; Tozkir H; Gurkan H; Atli EI; Yalcintepe S; Atli E; Sezer YA; Eker D; Tuncbilek N; Tastekin E; Ozen Y; Cicin I
J BUON; 2020; 25(3):1337-1347. PubMed ID: 32862574
[TBL] [Abstract][Full Text] [Related]
36. Prevalence and predictors of germline BRCA1 and BRCA2 mutations among young patients with breast cancer in Jordan.
Abdel-Razeq H; Abujamous L; Abunasser M; Edaily S; Bater R
Sci Rep; 2021 Jul; 11(1):14906. PubMed ID: 34290354
[TBL] [Abstract][Full Text] [Related]
37. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Kwan E; Jack E; Vesprini DJ; Kuperstein G; Abrahamson JL; Fan I; Wong B; Narod SA
Am J Hum Genet; 2001 Mar; 68(3):700-10. PubMed ID: 11179017
[TBL] [Abstract][Full Text] [Related]
38. Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study.
Uson PLS; Samadder NJ; Riegert-Johnson D; Boardman L; Borad MJ; Ahn D; Sonbol MB; Faigel DO; Fukami N; Pannala R; Kunze K; Golafshar M; Klint M; Esplin ED; Nussbaum RL; Stewart AK; Bekaii-Saab T
Clin Transl Gastroenterol; 2021 Oct; 12(10):e00414. PubMed ID: 34620795
[TBL] [Abstract][Full Text] [Related]
39. Low BRCA1 and BRCA2 Germline Mutation Rates in a French-Canadian Population with a Diagnosis of Epithelial Tubo-Ovarian Carcinoma.
Bernard J; Mehros W; Gregoire J; Douville P; Renaud MC; Sebastianelli A; Langlais EL; Plante M
J Obstet Gynaecol Can; 2022 Oct; 44(10):1047-1053. PubMed ID: 35779836
[TBL] [Abstract][Full Text] [Related]
40. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]